Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Validation of a Multi-gene Test for Lung Cancer Risk
NCT01130285 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to determine the validity of a multi-gene Lung Cancer Risk Test (LCRT). In the process, the investigators will establish a bank of NBEC samples and corresponding blood samples from individuals demographically at increased risk for lung cancer.
Conditions Studied
Interventions
- GENETIC Lung Cancer Risk Test
Study Locations (13)
Ohio
- Cleveland Clinic Foundation — Cleveland
- Ohio State University — Columbus
- The Toledo Hospital — Toledo
- Mercy St. Vincent Medical Center — Toledo
- University of Toledo, Health Science Campus — Toledo
Michigan
- University of Michigan — Ann Arbor
- Henry Ford — Detroit
Tennessee
- Tennessee Valley Veterans Admin. — Nashville
- Vanderbilt — Nashville
Colorado
- National Jewish Health — Denver
Minnesota
- Mayo Clinic — Rochester
South Carolina
- Medical University of South Carolina — Charleston
Virginia
- Inova Fairfax Hospital — Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2011-05 |
| Est. Completion | 2026-09 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01130285
The ClinicalTrials.gov registry entry for NCT01130285 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Toledo Health Science Campus, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention — of which Lung Cancer Risk Test is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01130285 reports 13 study locations spanning 7 distinct geographic areas — top geographies include Ohio, Michigan, Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01130285 about?
NCT01130285 is a clinical study titled "Validation of a Multi-gene Test for Lung Cancer Risk". The purpose of this study is to determine the validity of a multi-gene Lung Cancer Risk Test (LCRT). In the process, the investigators will establish a bank of NBEC samples and corresponding blood samples from individuals demographically at increased risk for lung cancer.
What is the current status of trial NCT01130285?
This trial is currently active not recruiting. The enrollment target is 403 participants. The study started on 2011-05. Estimated completion is 2026-09.
What conditions does trial NCT01130285 study?
This clinical trial studies the following conditions: Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01130285?
The interventions under investigation include: Lung Cancer Risk Test (GENETIC). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01130285?
This trial is sponsored by University of Toledo Health Science Campus, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01130285 being conducted?
This trial has 13 study locations across Colorado, Michigan, Minnesota, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.